Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kakar, Sham S ^a,b   Ratajczak, Mariusz Z ^a,b   Powell, Karen S ^c   Moghadamfalahi, Mana ^a   Miller, Donald M ^a,b   Batra, Surinder K ^d   Singh, Sanjay K ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CD34 ANTIGEN; CISPLATIN; HERMES ANTIGEN; NOTCH1 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR HES 1; WITHAFERIN A; TUMOR MARKER; WITHANOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; FEMALE; HES1 GENE; HEY1 GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MARKER GENE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NOTCH1 GENE; OVARY CANCER; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL DIVISION; DRUG EFFECTS; METABOLISM; NEOPLASM; NEOPLASM METASTASIS; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WITHANOLIDES;

EID: 84907500419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107596     Document Type: Article

References (86)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63: 11-30.
2. Hunn J, Rodriguez GC (2012) Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 55: 3-24.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer. Version 1.2013. Available: HTTP://www.nccn. org/professionals/physician-gls/pdf/ovarian.pdf
4. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, et al. (2003) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13 Suppl 2: 144-148.
5. Matsuo K, Lin YG, Roman LD, Sood AK (2010) Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19: 1339-1354.
6. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
7. El-Awady SE, Moustafa YM, Abo-Elmatty DM, Radwan A (2011) Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 650: 335-41.
8. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24(1): 19-38.
9. Lieberthal W, Triaca V, Levine J (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270: F700-708.
10. Kakar SS, Jala VR, Fong MY (2012) Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines. Biochem Biophys Res Commun 423: 819-825.
11. Fugner A (1973) Inhibition of immunologically induced inflammation by the plant steroid withaferin A. Arzneimittelforschung 23: 932-935.
12. Rasool M, Varalakshmi P (2006) Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: An in vivo and in vitro study. Vascul Pharmacol 44: 406-410.
13. Scartezzini P, Speroni E (2000) Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol 71: 23-43.
14. Gupta SK, Mohanty I, Talwar KK, Dinda A, Joshi S, et al. (2004) Cardioprotection from ischemia and reperfusion injury by Withania somnifera: a hemodynamic, biochemical and histopathological assessment. Mol Cell Biochem 260: 39-47.
15. Stan SD, Hahm ER, Warin R, Singh SV (2008) Withaferin A causes FOXO3a-and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 68: 7661-7669.
16. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, et al. (2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7: 115-122.
17. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D (2007) Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 67: 246-253.
18. Stan SD, Zeng Y, Singh SV (2008) Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 60 Suppl 1: 51-60.
19. Munagala R, Kausar H, Munjal C, Gupta RC (2011) Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 32: 1697-16705.
20. Yu Y, Hamza A, Zhang T, Gu M, Zou P, et al. (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79: 542-551.
21. Mayola E, Gallerne C, Esposti DD, Martel C, Pervaiz S, et al. (2011) Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 16: 1014-1027.
22. Choi MJ, Park EJ, Min KJ, Park JW, Kwon TK (2011) Endoplasmic reticulum stress mediates withaferin A induced apoptosis in human renal carcinoma cells. Toxicol In Vitro 25: 692-698.
23. Samadi AK, Mukerji R, Shah A, Timmermann BN, Cohen MS (2010) A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo. Surgery 148: 1228-1236.
24. Samadi AK, Tong X, Mukerji R, Zhang H, Timmermann BN, et al. (2010) Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma. J Nat Prod 73: 1476-1481.
25. Shah N, Kataria H, Kaul SC, Ishii T, Kaur G, et al. (2009) Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: combinational approach for enhanced differentiation. Cancer Sci 100: 1740-1747.
26. Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, et al. (2008) Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis 13: 1494-1504.
27. Oh JH, Kwon TK (2009) Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol 9: 614-619.
28. Mayola E, Gallerne C, Esposti DD, Martel C, Pervaiz S, et al. (2011) Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 16: 1014-27.
29. Roy RV, Suman S, Das TP, Luevano JE, Damodaran C (2013) Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod 76: 1909-1915.
30. Malik F, Kumar A, Bhushan S, Khan S, Bhatia A, et al. (2007) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 12: 2115-2133.
31. Lee TJ, Um HJ, Min do S, Park JW, Choi KS, et al. (2009) Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and downregulation of c-FLIP. Free Radic Biol Med 46: 1639-1649.
32. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, et al. (2011) Withaferin a-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One 6: e23354.
33. Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C (2010) Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 9: 202-210.
34. Hermann PC, Huber SL, Heeschen C (2008) Metastatic cancer stem cells: a new target for anti-cancer therapy? Cell Cycle 7: 188-193.
35. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
36. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
37. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367: 645-648.
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
39. Medema JP (2013) Cancer stem cells: the challenges ahead. Nat Cell Biol 15: 338-344.
40. Chen L, Kasai T, Li Y, Sugii Y, Jin G, et al. (2012) A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One 7: e33544.
41. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C (2012) Defining the mode of tumour growth by clonal analysis. Nature 488: 527-530.
42. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, et al. (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337(6095): 730-735.
43. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
44. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284.
45. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029.
46. Kurrey NK, Amit K, Bapat SA (2005) Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gyne Oncol 97: 155-165.
47. Zhang S, Balch C, Chan MW, Lai HC, Matei D, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors, Cancer Res 68: 4311-4320.
48. Deng S, Yang X, Lassus H, Liang S, Kaur S, et al. (2010) Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 5: e10277.
49. Silva IA, Bai S, McLean K, Yang K, Griffith K, et al. (2011) Aldehyde dehydrogenase and CD133 define angiogenic ovarian cancer stem cells that portend poor patient survival, Cancer Res 71: 3991-4001.
50. Dyall S, Gayther SA, Dafou D (2010) Cancer stem cells and epithelial ovarian cancer. J Oncol 2010: 105269.
51. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8: 158-166.
52. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
53. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, et al. (2013) Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell like cells leading to an increased tumor burden. Mol Cancer 12: 24.
54. Malik MT, Kakar SS (2006) Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer 5: 61.
55. Nunez-Cruz S, Connolly DC, Scholler N (2010) An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses. J Vis Exp 28.pii: 2146.
56. Fong MY, Jin S, Rane M, Singh RK, Gupta R, et al. (2012) Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One 7: e42265.
57. Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, et al. (2014) Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells. J Cancer 5: 301-310.
58. Ramdass B, Duggal R, Minev B, Chowdhary A, Koka P (2013) Functional role of solid tumor stem cells in disease etiology and susceptibility to therapeutic interventions. J Stem Cells 8: 189-231.
59. Ponnusamy MP, Batra SK (2008) Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res, 1: 4.
60. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, et al. (2009) Stem like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 7: 2405-2413.
61. Reya T, Clevers H (2005) Wnt signaling in stem cells and cancer. Nature 434: 843
62. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al. (2006) Hedgehogsignaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071.
63. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, et al. (2004) Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells, Breast Cancer Res 6: 605-615.
64. Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: wnt signaling in cancer, Biochim Biophys Acta 1653: 1-24.
65. Mimeault M, Batra SK (2012) Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol 3: 32-42.
66. Wu KJ, Yang MH (2011) Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1connection. Biosci Rep 31: 449-455.
67. Jain P, Alahari SK (2011) Breast cancer stem cells: a new challenge for breast cancer treatment. Front Biosci 16: 1824-1832.
68. Suman S, Das TP, Damodaran C (2013) Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer, 109: 2587-2596.
69. Shi W, Harris AL (2006) Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11: 41-52.
70. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A (2013) Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 13: 7-15.
71. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177: 1053-1064.
72. Christen RD, Isonishi S, Jones JA, Jekunen AP, Hom DK, et al. (1994) Signaling and drug sensitivity. Cancer Metastasis Rev 13: 175-189.
73. Brown R, Clugston C, Burns P, Edlin A, Vasey P, et al. (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684.
74. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, et al. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-62.
75. Hollier BG, Evans K, Mani SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14: 29-43.
76. Ahmed N, Abubaker K, Findlay J, Quinn M (2010) Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10: 268-278.
77. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, et al. (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7: e46858.
78. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29: 2672-2680.
79. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, et al. (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9: 3186-3199.
80. Guo X, Xiong L, Sun T, Peng R, Zou L, et al. (2012) Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol 7: 44.
81. Surowiak P, Materna V, Maciejczyk A, Kaplenko I, Spaczynski M, et al. (2006) CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer Res 26: 4943-4948.
82. Oh DH, Kim SH, Jung S, Sung YK, Bang SY, et al. (2011) Precuneus hypoperfusion plays an important role in memory impairment of patients with systemic lupus erythematosus. Lupus 20: 855-860.
83. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, et al. (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18: 869-881.
84. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103: 11154-11159.
85. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, et al. (2012) Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 7: e29079.
86. Kwon MJ, Shin YK (2013) Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci 14: 6624-6648.